AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Flagship Awards CEO of Agios Pharmaceuticals the Entrepreneur of the Year Award

Flagship Awards CEO of Agios Pharmaceuticals the Entrepreneur of the Year Award

November 21, 2016

This week, Flagship held the Firm’s Annual Meeting in Boston. Each year at this meeting we recognize an executive from a portfolio company who demonstrates great passion for and commitment to pioneering advancements in the life sciences. The recipient of this year’s award is David Schenkein, M.D., chief executive officer of Agios Pharmaceuticals (NASDAQ: AGIO).

Moderna Named a Boston Globe 2016 Top Places to Work

Moderna Named a Boston Globe 2016 Top Places to Work

November 17, 2016

The Boston Globe has announced the results of its annual Top Places to Work survey, and Flagship portfolio company Moderna Therapeutics was honored as one of just six biopharma companies on the list. Learn more from the Boston Globe about the survey and the results here: http://bit.ly/2fMRMrZ

Moderna Named 2016 Top Employer by Science Magazine

Moderna Named 2016 Top Employer by Science Magazine

October 27, 2016

 

Moderna has been named by Science magazine as a 2016 Top Employer.

Read more.

Axcella Health

Axcella Health Named a Fortune 2016 Best Small & Medium Workplace

Axcella Health Named a Fortune 2016 Best Small & Medium Workplace

October 12, 2016

 

Read more.

Viewpoint: Why we’re doubling down in Massachusetts (from the Boston Business Journal)

Viewpoint: Why we’re doubling down in Massachusetts (from the Boston Business Journal)

October 6, 2016

 

As scientists from all over the world convene in Boston for Biotech Week, my company is doubling down in Massachusetts. Flagship Ventures is moving its headquarters – but we have decided to stay in Kendall Square, where we put down roots almost two decades ago. Since our founding in 2000 we have both contributed to and witnessed the progress that has made Massachusetts a leader for innovation and the world’s epicenter of biotechnology.

An Audience With Michael Rosenblatt

An Audience With Michael Rosenblatt

September 29, 2016

From Nature Reviews Drug Discovery:

Although biopharma start-up companies have to be laser-focused on translational science, this single-mindedness sometimes comes at the expense of clinical development expertise. The venture capital group Flagship Ventures has now named Michael Rosenblatt as Chief Medical Officer to help its portfolio of companies fill that experience gap. Rosenblatt was Chief Medical Officer at Merck & Co. for 7 years prior to this role, and Dean of Tufts University School of Medicine before that.

Moderna

Moderna Appoints Annie Seibold Drapeau as Chief Human Resources Officer

Moderna Appoints Annie Seibold Drapeau as Chief Human Resources Officer

October 6, 2016

Bain Capital operating partner and former human resources tech executive to lead Moderna’s talent and organizational strategy to support company’s continued growth and pipeline advancement.

Moderna to Build State-of-the-Art Fully Integrated GMP mRNA Clinical Manufacturing Facility in Norwood, Mass.

Moderna to Build State-of-the-Art Fully Integrated GMP mRNA Clinical Manufacturing Facility in Norwood, Mass.

September 21, 2016

-Key component of Moderna’s early development engine, designed to simultaneously advance many mRNA medicines across the company’s broad therapeutic portfolio-

-Initial investment of $110M to build out 200,000 square foot facility; Will employ more than 200 employees-

-Fully integrated site from raw material to API, formulation, filling and finish-